Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake
Journal of Clinical Investigation · 01.05.2025 · 135 (9)
DOI: 10.1172/jci188314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 06.03.2025. Verfasst von Mehdi Farokhnia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intr…. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Alcohol Drinking, Alcoholism. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, BLRD VA, Intramural NIH HHS.
Abstract (Originalsprache)
BACKGROUND Despite growing preclinical evidence that glucagon-like peptide1 receptor agonists (GLP-1RAs) could be repurposed to treat alcohol use disorder (AUD), clinical evidence is scarce. Additionally, the potential impact of dipeptidyl peptidase-4 inhibitors (DPP-4Is) on alcohol intake is largely unknown. METHODS We conducted a large cohort study using 2008–2023 electronic health records data from the U.S. Department of Veterans Affairs. Changes in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) scores were compared between propensity-score–matched GLP-1RA recipients, DPP-4I recipients, and unexposed comparators. We further tested the effects of 2 DPP-4Is, linagliptin and omarigliptin, on binge-like alcohol drinking in mice and operant oral alcohol self administration in alcohol-dependent rats, models previously used to show a significant effect of the GLP-1RA semaglutide in reducing alcohol intake. RESULTS GLP-1RA recipients reported a greater reduction in AUDIT-C scores than unexposed individuals (difference-in-difference [DiD]: 0.09 [95% CI: 0.03, 0.14], P = 0.0025) and DPP-4I recipients (DiD: 0.11 [95% CI: 0.05,0.17], P = 0.0002). Reductions in drinking were more pronounced among individuals with baseline AUD (GLP-1RA versus unexposed: 0.51 [95% CI: 0.29,0.72], P < 0.0001; GLP-1RA versus DPP-4I: 0.65 [95% CI: 0.43,0.88], P < 0.0001) and baseline hazardous drinking (GLP-1RA versus unexposed: 1.38 [95% CI: 1.07,1.69], P < 0.0001; GLP-1RA versus DPP-4I: 1.00 [95% CI: 0.68,1.33], P < 0.0001). There were no differences between DPP-4I recipients and unexposed individuals. The latter results were confirmed via a reverse translational approach. Specifically, neither linagliptin nor omarigliptin reduced alcohol drinking in mice or rats. The rodent experiments also confirmed target engagemhent, as both DPP-4Is reduced blood glucose levels. CONCLUSION Convergent findings across humans, mice, and rats indicated that GLP-1RAs, but not DPP-4Is, reduce alcohol consumption and may be efficacious in treating AUD. FUNDING This work was supported by the National Institutes of Health Intramural Research Program (ZIA DA000635, ZIA DA000644, ZIA DA000602), National Institute on Alcohol Abuse and Alcoholism extramural funding (R01 AA030041, P01 AA029545, U01 AA026224, U24 AA020794, U01 AA020790, U10 AA013566), the U.S. Department of Veterans Affairs (I01BX004820), and an Alkermes Pathways Research Award.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Al…
- Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
- Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.
- Neurobiology of Addiction Section, Integrative Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, NIH, Baltimore, Maryland, USA.
- Stress & Addiction Neuroscience Unit, Integrative Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural…
- Department of Medical and Clinical Psychology, Uniformed Services University, Bethesda, Maryland, USA.
Förderung
- NIAAA NIH HHS
- BLRD VA
- Intramural NIH HHS
- National Institutes of Health intramural funding
- National Institute on Alcohol Abuse and Alcoholism extramural funding
- U.S. Department of Veterans Affairs
- Alkermes Pathways Research Awards Program
Zitieren
APA
Farokhnia, M., Tazare, J., Pince, C. L., Bruns, N., Gray, J. C., Lo Re, V., Fiellin, D. A., Kranzler, H. R., Koob, G. F., Justice, A. C., Vendruscolo, L. F., Rentsch, C. T., & Leggio, L. (2025). Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. Journal of Clinical Investigation, 135(9). https://doi.org/10.1172/jci188314
Vancouver
Farokhnia M, Tazare J, Pince CL, Bruns N, Gray JC, Lo Re V, et al. Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake. Journal of Clinical Investigation. 2025;135(9). doi:10.1172/jci188314
BibTeX
@article{Farokhnia2025,
author = {Farokhnia, Mehdi and Tazare, John and Pince, Claire L and Bruns, Nicolaus and Gray, Joshua C and Lo Re, Vincent and Fiellin, David A and Kranzler, Henry R and Koob, George F and Justice, Amy C and Vendruscolo, Leandro F and Rentsch, Christopher T and Leggio, Lorenzo},
title = {Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {9},
doi = {10.1172/jci188314}
}
EUVIMED